公开(公告)号：EP1791968A4

公开(公告)日：2009-05-13

申请号：EP05791237

申请日：2005-08-25

申请人： CELL GENESYS INC

发明人： POLICE SESHIDAR REDDY ,  GANESH SHANTHI ,  YU DECHAO

IPC分类号： C12P21/06 ,  A01N63/00 ,  A61K39/12 ,  C12N15/00 ,  C12N15/64 ,  C12N15/83

CPC分类号： C12N15/86 ,  A61K35/13 ,  A61K48/00 ,  A61K2039/5152 ,  C12N7/00 ,  C12N2710/10322 ,  C12N2710/10343 ,  C12N2710/10345

摘要： Adenoviral vectors which effectively transduce primary tumor cells are provided. The adenoviral vectors comprise a chimeric adenovirus fiber protein which includes at least a portion of a Subgroup C adenovirus fiber shaft and at least a portion of a Subgroup B adenovirus or serotype 37 adenovirus head, wherein the head region binds CD46.

公开(公告)号：EP0950707B1

公开(公告)日：2009-02-18

申请号：EP99108460.9

申请日：1990-07-25

申请人： CELL GENESYS, INC.

发明人： Kucherlapati, Raju S. ,  Koller, Beverly H. ,  Smithies, Oliver

IPC分类号： C12N15/00 ,  A01K67/027 ,  C07K14/705

CPC分类号： C12N15/8509 ,  A01K67/0271 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/025 ,  A01K2267/03 ,  C07K14/70539 ,  C12N15/00

公开(公告)号：EP2007896A2

公开(公告)日：2008-12-31

申请号：EP07754417.9

申请日：2007-03-28

申请人： Cell Genesys Inc.

发明人： LI, Betty ,  DU, Thomas ,  JOOSS, Karin

IPC分类号： C12P1/00

CPC分类号： A61K45/06 ,  A61K31/517 ,  A61K48/0083 ,  C07K14/535 ,  A61K2300/00

摘要： The present invention in all of its associated aspects provides improved methods and compositions for treating cancer in a mammal based on the sequential administration of the combination of a cytokine-expressing cancer immunotherapy composition and at least one tyrosine kinase inhibitor, wherein administration of the combination results in enhanced therapeutic efficacy relative to administration of the cytokine-expressing cancer immunotherapy composition or at least one tyrosine kinase inhibitor as a monotherapy.

公开(公告)号：EP1268761B1

公开(公告)日：2008-12-31

申请号：EP01918927.3

申请日：2001-03-21

申请人： CELL GENESYS, INC.

发明人： YU, De-Chao ,  ZHANG, Hong ,  HENDERSON, Daniel, R.

IPC分类号： C12N15/00

CPC分类号： C12N15/86 ,  A61K48/00 ,  C07K14/4702 ,  C12N2710/10343 ,  C12N2710/10345 ,  C12N2830/008 ,  C12N2830/85 ,  C12N2840/20 ,  C12N2840/203

摘要： The invention provides new urothelial cell specific transcriptional regulatory sequences derived from human uroplakin II hUPII, as well as polynucleotide constructs such as adenoviral vectors and methods of using hUPII-derived TREs. Additionally, the invention provides adenoviral vectors comprising a gene, preferably an adenovirus gene, under transcriptional control of a urothelial cell-specific transcriptional regulatory element (TRE). These vectors display urothelial cell-specific cytotoxicity, which is especially useful in the context of bladder cancer, in which destruction of these cells is desirable. The invention further provides compositions and host cells comprising the vectors, as well as method of using the adenoviral vectors.

公开(公告)号：EP1863915A4

公开(公告)日：2008-07-16

申请号：EP06736345

申请日：2006-02-28

申请人： CELL GENESYS INC

发明人： FREY DAVID ,  SHU CASSANDRA

IPC分类号： C12N15/63

CPC分类号： C12N15/86 ,  C12N7/00 ,  C12N2710/10321 ,  C12N2710/10343 ,  C12N2710/10351

摘要： Therapeutic viral formulations having enhanced storage stability are described. The formulations comprise a viral vector in addition to one or more of an aqueous cosolvent, a reversible viral-encoded protease inhibitor and a mild reducing agent or other agent that prevents specific degradation of viral components.

公开(公告)号：EP0972063B1

公开(公告)日：2008-01-30

申请号：EP98908871.1

申请日：1998-03-03

申请人： CELL GENESYS, INC.

发明人： LITTLE, Andrew, S. ,  LAMPARSKI, Henry, G. ,  HENDERSON, Daniel, R. ,  SCHUUR, Eric, R.

IPC分类号： C12N15/86 ,  C12N7/00

CPC分类号： C12N15/86 ,  A61K38/00 ,  A61K48/00 ,  C07K14/005 ,  C07K14/4715 ,  C12N15/63 ,  C12N2710/10322 ,  C12N2710/10343 ,  C12N2710/10345 ,  C12N2830/002 ,  C12N2830/008

摘要： Adenovirus vectors replication specific for cells expressing α-fetoprotein (AFP) and their methods of use are provided. By providing for a transcriptional initiating regulation dependent upon AFP expression, virus replication is restricted to target cells expressing AFP, particularly hepatocellular carcinoma cells. The adenovirus vectors can be used to detect and monitor samples for the presence of AFP-producing cells as well as to kill selectively malignant cells producing AFP.

公开(公告)号：EP1877429A2

公开(公告)日：2008-01-16

申请号：EP06749906.1

申请日：2006-04-11

申请人： CELL GENESYS, INC.

发明人： HARDING, Thomas ,  NGUYEN, Minh

IPC分类号： C07K14/435 ,  C07K14/705 ,  C12N5/10 ,  C12N15/12 ,  C12N15/62 ,  C12N15/63

CPC分类号： C07K14/71 ,  C07K2319/30 ,  C07K2319/70 ,  C12N2830/205 ,  C12N2840/203

摘要： Multivalent soluble receptor proteins that bind to more than one angiogenic factor are described. Nucleotide and vector sequences which encode the multivalent soluble receptor protein, as well as host cells which comprise them and methods of making and using them are also described. The multivalent soluble receptor proteins and vectors which encode them find utility in treatment of cancer and other diseases associated with angiogenesis.

公开(公告)号：EP1129100B1

公开(公告)日：2007-07-11

申请号：EP99962651.8

申请日：1999-11-12

申请人： Cell Genesys Inc.

发明人： MCGUINNESS, Ryan, Cell Genesys Inc. ,  NALDINI, Luigi, Cell Genesys Inc.

IPC分类号： C07H21/00 ,  C07H21/04 ,  C12N15/00 ,  C12N15/09 ,  C12N15/63 ,  C12N15/70 ,  C12N15/74 ,  C12N15/86 ,  C12N5/10

CPC分类号： C12N15/86 ,  C12N2740/16052

摘要： A method for selecting packaging cells that express high levels of gag/pol is provided.

公开(公告)号：EP0742723B1

公开(公告)日：2007-06-06

申请号：EP95906116.9

申请日：1994-12-28

申请人： CELL GENESYS, INC. ,  UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

发明人： KUCHERLAPATI, Raju ,  KOLLER, Beverly, H. ,  SMITHIES, Oliver ,  DUBRIDGE, Robert, B. ,  GREENBURG, Gary ,  CAPON, Daniel, J. ,  WILLIAMS, Steven, R. ,  LOURDES ARBONES DE RAFAEL, Maria

IPC分类号： A61K49/00 ,  C07H21/00 ,  C12N15/00 ,  C12Q1/68

CPC分类号： A01K67/0271 ,  A01K67/0275 ,  A01K67/0276 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/025 ,  A01K2267/03 ,  A01K2267/0381 ,  C07K14/70539 ,  C12N15/00 ,  C12N15/8509

摘要： Homologous recombination is employed to inactivate genes, particularly genes associated with MHC antigens. Particularly, the β2-microglobulin gene is inactivated for reducing or eliminating the expression of functional Class I MHC antigens. The resulting cells may be used as universal donor cells. In addition, embryonic stem cells may be modified by homologous recombination for use in producing chimeric or transgenic mammalian hosts, which may be used as source of universal donor organs, or as models for drug and transplantation therapies. Methods for homologous recombination in non-transformed mammalian somatic cells are also described.

公开(公告)号：EP1789082A1

公开(公告)日：2007-05-30

申请号：EP05796370.4

申请日：2005-09-09

申请人： CELL GENESYS, INC.

发明人： LIU, Pocheng ,  WU, Kuoting, Anthony ,  SY, Johanna ,  BORELLINI, Flavia

IPC分类号： A61K39/00 ,  A01N63/00 ,  G01N33/537 ,  A61K48/00

CPC分类号： A61K39/0011 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/55522 ,  A61K2039/57 ,  C12N15/86 ,  C12N2710/10343 ,  C12N2740/13043 ,  C12N2800/108 ,  C12N2800/30 ,  C12N2810/60 ,  C12N2830/42

摘要： Genetically modified cytokine-expressing cells for use as vaccines in the treatment of prostate cancer are provided. More specifically, genetically modified, GM-CSF expressing cells as a means to generate an enhanced immune response to beta filamin and the use thereof in the treatment of prostate cancer are described.